NEW research has shown that anti-CGRP monoclonal antibodies (mAbs) are not associated with an increased cardiovascular disease (CVD) risk, compared to onabotulinumtoxinA among, Medicare beneficiaries ...

Will the new AHS position convince insurers to ... Many people with migraine find relief from combination therapy, where the older migraine prevention drugs may work in tandem with the newer ...

5-hydroxytriptamine is a key mediator in the pathogenesis of migraine and thus 5-HT 1-receptor agonists are the principal drugs for acute migraine therapy ... attacks. New drugs with improved ...

There's new hope for the millions of people who suffer with frequent migraines. In what is a huge breakthrough, the FDA has now approved a first-of-its-kind targeted therapy designed to prevent ...

Dr Vaid said: "Bringing this new therapy to patients represents an exciting step forward in migraine management. Chronic Migraine has a profound impact on people's lives, limiting daily activities ...

Nevertheless, a substantial number of migraine-affected individuals are unresponsive to triptans, and such therapy can also lead to an array of adverse effects. A new class of antimigraine drugs ...

You can also get in touch in the following ways: Atogepant is a new type of anti-calcitonin gene-related peptide (CGRP) drug, which is specifically designed to treat migraines. They work by ...

AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic ... as well as for acute treatment of migraine attacks. The Migraine Trust said that the new drugs are important ...

A migraine charity said it brought "new hope", especially for those who ... aged eight and has tried every type of medicine or therapy available, including acupuncture, but nothing really helps.

Now, John et al. have demonstrated the benefits of yoga therapy in the treatment of migraine. The researchers enrolled 72 patients who had migraine without aura. Following a 4-week run-in period ...

The objective of this review is to provide an overview of the CV effects of migraine therapy to empower clinicians with the ability to initiate or modify migraine therapy in a patient with CV ...

Collegium Pharma has expanded its pain franchise though a deal to acquire BioDelivery Sciences International (BDSI), which has three FDA-approved drugs and a new migraine therapy due to launch in ...